Sergey Yurasov compensation by year
Black Diamond Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $488,250 | $507,800 | $525,600 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $189,000 |
| Option awards | $514,760 | $788,851 | $402,348 |
| Non-equity incentive | $205,065 | $197,026 | $212,342 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $25,609 | $21,143 | $22,806 |
| Total | $1,233,684 | $1,514,820 | $1,352,097 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Black Diamond Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-051474, and prior-year filings.
How this page was built: the Black Diamond Therapeutics, Inc. filed document, accession 0001104659-26-051474. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 75,000 | $182,250 | — |
| Option | 121,876 | — | $4.86 |
| Option | 31,253 | — | $1.69 |
| Option | 72,919 | — | $2.92 |
| Option | 200,000 | — | $2.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Black Diamond Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Black Diamond Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Velleca | President and Chief Executive Officer | $2,234,919 |
| Sergey Yurasov · this page | Chief Medical Officer | $1,352,097 |
| Brent Hatzis-Schoch | Chief Operating Officer and General Counsel | $1,282,245 |
Sergey Yurasov's compensation dossier, Black Diamond Therapeutics
You have read Sergey Yurasov's totals and holdings. The dossier adds each equity grant Black Diamond Therapeutics disclosed for Sergey Yurasov and Black Diamond Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Black Diamond Therapeutics compensation record
free company briefThis page is one person within Black Diamond Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Black Diamond Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Black Diamond Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.